ev3 EVVV
-
Pharma Spin-Off Should Unlock Value of Covidien's Well-Positioned Device Business
… come through acquisitions, most notably the 2010 purchase of ev3 , which contributed about $500 million to the top line and bolstered ..... has averaged 7.5%, the device segment (adjusted for the ev3 acquisition and sharp safety and radiopharma reclassification …
-
New Morningstar Analyst Report - Covidien, Ltd.
… business, and tends not to rely too aggressively on acquisitions to bolster its market share. While we initially viewed the ev3 purchase as pricey, we have since changed our stance on it and now view the returns on this investment as accretive to the overall …
-
Covidien's 4Q In Line; Maintaining Outlook for 2012
… growth challenging. We're impressed by the progress of the ev3 business, with expectations for top-line internal growth in ..... general, and administrative expense for the first time since the ev3 acquisition. We anticipate this trend will continue into 2012 …
-
UPDATE 3-Wright Medical taps veteran exec as CEO, shrs jump
* Names Robert Palmisano, previously ev3 chief, as new CEO
-
Covidien's 3Q Slightly Above Our Forecast; We Plan to Raise Fair Value Estimate
… sealing products continued to take share. The vascular product line posted double-digit growth as well (once adjusted for the ev3 acquisition); the company said all three major acquisitions it completed over the past year are exceeding internal expectations …
-
Our Outlook for Health-Care Stocks
… wave of new product introductions and likely share gains in vascular treatment following the integration of recently acquired ev3 's operations. The company should see an uptick in elective procedures as surgery deferrals witnessed during the past few years …
-
Covidien's Profit Improves on Product Mix, Cost Reductions, Lower Tax Rate
… exceeding our expectations ever since the ev3 acquisition, and we are now less critical ..... margin business lines and the acquisition of ev3 ) on the gross margin should dissipate through ..... significant investor backlash following the ev3 deal. The firm also suggested that based …
-
Our Outlook for Health-Care Stocks
… wave of new product introductions and likely share gains in vascular treatment following the integration of recently acquired ev3 's operations. The company should see an uptick in elective procedures as surgery deferrals witnessed during the past few years …
-
Covidien Sees Improvement in U.S. Procedures, Delivers Strong Cash Flows in 4Q
… Devices overall grew 10% in constant currency, with vascular, energy, oximetry and monitoring posting strong results. The ev3 integration is proceeding smoothly, evidenced in part by a high-teens organic growth in the vascular business. This performance …
-
Boston Scientific May Sell Unit to Stryker
… There are also rumors that Boston may sell its neurovascular unit . Based on the $ 2 . 6 billion Covidien COV recently paid for ev3 's roughly $ 500 million in annual sales , we put Boston's neurovascular business in the ballpark of $ 1 . 5 billion . We …